Form 4: Xeris Biopharma CLO Beth Hecht Sells Shares

Chief Legal Officer Beth Hecht sold 16,667 shares of Xeris Biopharma Holdings, Inc. common stock via a 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 16,667 shares of common stock.
• The transaction occurred on June 1, 2026, at a weighted average price of $6.0588 per share.
• The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 1,176,506 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard for executive financial planning.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's current valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the range upon request.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice in the biopharmaceutical sector and typically does not indicate a change in fundamental company strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and represents a small portion of the officer's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Beth Hecht, Equity Sale